MAM
RCUS icon

Meeder Asset Management’s Arcus Biosciences RCUS Stock Holding History

Meeder Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12
Closed – – 1723
2022
Q3 		$0 Sell
12
-18
-60% -$476 ﹤0.01% 2319
2022
Q2 		$1K Buy
+30
New +$735 ﹤0.01% 2063
2020
Q3 		– Sell
-1,883
Closed -$45K – 2335
2020
Q2 		$45K Sell
1,883
-1,284
-41% -$34.7K ﹤0.01% 947
2020
Q1 		$45K Buy
3,167
+1,906
+151% +$23.7K ﹤0.01% 949
2019
Q4 		$13K Sell
1,261
-3,678
-74% -$30.9K ﹤0.01% 1489
2019
Q3 		$46K Buy
4,939
+4,300
+673% +$34.6K ﹤0.01% 1044
2019
Q2 		$5K Buy
639
+297
+87% +$2.97K ﹤0.01% 1674
2019
Q1 		$4K Buy
+342
New +$3.71K ﹤0.01% 1454

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Meeder Asset Management's RCUS Position: Q4 2022 in Review

Meeder Asset Management sold out of Arcus Biosciences (RCUS) in Q4 2022, closing a stake of 12 shares.

Meeder Asset Management first reported a position in RCUS in Q1 2019 and held it in 8 quarters. The position peaked at $46K in Q3 2019. 200 funds tracked by Wall St. Rank hold RCUS as of Q4 2022.

  • Meeder Asset Management reported no remaining Arcus Biosciences position as of Q4 2022 after selling out during the quarter.
  • Meeder Asset Management sold 12 Arcus Biosciences shares in Q4 2022.
  • Meeder Asset Management first reported a position in Arcus Biosciences in Q1 2019 and held it in 8 quarters.
  • Meeder Asset Management's Arcus Biosciences position peaked at $46K in Q3 2019.
  • 200 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.